alog_pcfb.RdA dataset from a systematic review of Randomised-Controlled Trials (RCTs) comparing different doses of alogliptin with placebo langford2016MBNMAdose. The systematic review was simply performed and was intended to provide data to illustrate a statistical methodology rather than for clinical inference. Alogliptin is a treatment aimed at reducing blood glucose concentration in type II diabetes. The outcome is continuous, and aggregate data responses correspond to the mean change in HbA1c from baseline to follow-up in studies of at least 12 weeks follow-up. The dataset includes 14 Randomised-Controlled Trials (RCTs), comparing 5 different doses of alogliptin with placebo, leading to 6 different treatments (combination of dose and agent) within the network.
alog_pcfbA data frame in long format (one row per arm and study), with 46 rows and 6 variables:
studyID Study identifiers
agent Character data indicating the agent to which participants were randomised
dose Numeric data indicating the standardised dose received
y Numeric data indicating the mean change from baseline in blood glucose concentration (mg/dL) in a study arm
se Numeric data indicating the standard error for the mean change from baseline in blood glucose concentration (mg/dL) in a study arm
n Numeric data indicating the number of participants randomised
alog_pcfb is a data frame in long format (one row per arm and study), with the variables studyID, agent, dose, y, se, and N.